Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05865457Not ApplicableRecruiting

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease

Role: lead

NCT05865379Not ApplicableRecruiting

Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease

Role: lead

NCT02688400Phase 3Completed

Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis

Role: lead

All 3 trials loaded